HK Stock Market Move | YOFC (06869) rises over 3%; the company's earnings visibility improves, and institutions expect shipment volume to grow 34% within the year.
YOFC (06869) rose over 3%, up 3.33% as of press time, at HK$3.7, with a turnover of HK$430 million.
YOFC (06869) rose over 3%, up 3.33% as of press time, at HK$3.7, with a turnover of HK$430 million.
On the news front, DBS released a research report pointing out that it upgraded YOFC's rating from "Fully Valued" to "Buy," with a target price of HK$259, based on 20 times the forecast price-to-earnings ratio for FY2027, one standard deviation above the historical average, reflecting improved earnings visibility, increased exposure to AI data center demand, and domestic telecom carriers' price reset.
The bank forecasts YOFC's shipment volume to grow 34%, 19%, and 9% in FY2026 to FY2028, respectively, with the group's gross profit margin expanding to 48% in FY2026; revenue to grow 63%, 44%, and 20%, respectively, and raised its profit forecasts to RMB 6.068 billion, RMB 9.313 billion, and RMB 11.199 billion, respectively.
Related Articles

Shenwan Hongyuan Group (06806): Zhang Xi nominated as candidate for non-executive director

Jiangsu Lopal Tech. Group (02465)'s second-tier controlling subsidiary, Nanjing Lihyuan, signed a Strategic Cooperation Framework Agreement with Jiyao Tongxing.

Lepu Medical Technology (300003.SZ) subsidiary receives U.S. FDA approval for clinical trial of MWN117 injection.
Shenwan Hongyuan Group (06806): Zhang Xi nominated as candidate for non-executive director

Jiangsu Lopal Tech. Group (02465)'s second-tier controlling subsidiary, Nanjing Lihyuan, signed a Strategic Cooperation Framework Agreement with Jiyao Tongxing.

Lepu Medical Technology (300003.SZ) subsidiary receives U.S. FDA approval for clinical trial of MWN117 injection.






